<DOC>
	<DOCNO>NCT01235234</DOCNO>
	<brief_summary>Eligible patient dry eye treat CF101 placebo twice daily 24 week . Disease activity assess use evaluation ocular surface integrity , tear production , patient symptom .</brief_summary>
	<brief_title>Trial CF101 Treat Patients With Dry Eye Disease</brief_title>
	<detailed_description>Patients randomize receive either CF101 0.1 mg , CF101 1.0 mg , match placebo , give orally twice daily ( BID ) 24 week . A Screening Period 4 week include 2-week run-in period precede 24-week treatment period , follow 2-week follow-up period . At Screening Visit , patient undergo complete medical ophthalmologic history , medication history , physical examination ( include height , weight , sit blood pressure , pulse rate temperature ) , ophthalmic examination , clinical laboratory test . Disease activity assess use fluorescein staining , Schirmer test without anesthesia , Ocular Surface Disease Index© , tear break-up time . Eligible patient begin 2-week run-in period 4-week screening period , time instructed discontinue use topical ophthalmic medication except REFRESH TEARS® Lubricant Eye Drops . At Baseline Visit , patient successfully complete 2-week run-in period re-qualify entry randomize assigned medication ( CF101 0.1 mg , CF101 1.0 mg , match placebo ) take orally twice daily BID 24 week . Patients return assessment new supply study medication Weeks 2 , 4 , 8 , 12 , 16 , 20 ; Week 24 final on-treatment assessment ; Week 26 2-week off-treatment follow-up visit .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<criteria>Male female , 18 year age ; Have diagnosis moderatetosevere AqueousDeficient Dry Eye ( include Sjögren 's Syndrome dry eye ) , define : 1 . Positive corneal fluorescein stain ( FS ) , define corneal punctate fluorescein stain score ≥4 either eye National Eye Institute evaluation scale sum 5 area 03 score scale ; AND 2 . FS score ≥2 least one corneal region ; AND 3 . Schirmer Test ( ST ) score ( without anesthesia ) ≥1 mm &lt; 7 mm/5 min either eye ; AND 4 . OSDI score ≥20 ; Central corneal FS score ≥2 least 1 eye ; Willing use topical ocular treatment , REFRESH® unpreserved artificial tear maximum 4 time daily , duration trial ( include 2week runin period , 24week treatment period 2week followup period ) ; Willing forego periocular cosmetic application duration trial ; Females childbearing potential must negative urine pregnancy test screen throughout study , eligible , continue participation , study ; Females childbearing potential must willing use 2 method contraception deem adequate Investigator ( example oral contraceptive pill plus barrier method ) eligible , continue participation , study ; Ability complete study compliance protocol ; Ability understand provide write informed consent . Sjögren 's Syndrome significant systemic nonexocrine gland involvement , investigator‟s opinion , would interfere conduct trial ; StevensJohnson Syndrome ; Use methotrexate systemic cyclosporine within 3 month prior Screening Visit ; diseasemodifying antirheumatic therapy within 2 month prior Screening Visit ; Use antirheumatic biological agent within 2 month , 5 halflives , whichever longer , prior Screening Visit ; Use oral corticosteroid &gt; 10 mg prednisone , equivalent , per day ; Use topical steroid within 4 week prior Screening Visit duration study ; Receipt topical cyclosporine eye drop within 3 month prior Screening Visit duration trial ; Use oral statin preparation contain omega3 fatty acid unless dose stable least 3 month remain course trial ; Presence chronic ocular disease AqueousDeficient Dry Eye require topical treatment ; Presence postburn ocular injury ; Ocular herpes simplex virus infection ; Concomitant use contact lenses use within 3 month prior Screening Visit ; Persistent intraocular inflammation infection ; Active anterior blepharitis great mild degree , define minimal crust base eyelash sign inflammation ; Meibomian gland dysfunction ( MGD ) great mild degree , define mild plug Meibomian gland without lid margin inflammation ; Surgical occlusion lacrimal puncta , include insertion punctual plug , within 3 month Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Dry eye disease</keyword>
	<keyword>KCS</keyword>
	<keyword>Aqueous Deficient Dry Eye</keyword>
</DOC>